Last updated: February 13, 2026
What Are the Patentability Criteria for Biopharmaceuticals in Malaysia?
Malaysia's Patent Act 1983, amended in 2008, outlines specific requirements for patentability:
-
Novelty: The invention must be new; it cannot have been disclosed publicly anywhere prior to the filing date.
-
Inventive Step: The invention must involve an inventive step not obvious to a person skilled in the field.
-
Industrial Applicability: The invention must have a specific, substantial, and credible utility.
-
Patentable Subject Matter: Per Section 13 of the Patent Act, certain biopharmaceutical inventions qualify, provided they are not explicitly excluded.
Excluded Subject Matter
Under Sections 13 and 15, the following are excluded:
-
Discoveries, scientific theories, and mathematical methods.
-
Plant or animal varieties, and essentially biological processes for their production.
-
Methods of surgical or therapeutic treatment of humans or animals.
-
Diagnostic methods practiced on humans or animals.
However, products such as biopharmaceutical compounds and purified biological molecules are patentable, provided they meet other criteria.
Implications for Biopharmaceutical Patents
Malaysia permits patent protection on novel biopharmaceutical molecules, formulations, and manufacturing processes. The scope is limited by exclusions relating to biological processes and methods rather than products per se.
How Enforceable Are Biopharmaceutical Patents in Malaysia?
Enforceability depends on adherence to statutory and procedural requirements:
-
Validity: A patent granted must be properly substantiated during examination, with sound inventive step and novel data.
-
Infringement: Patent infringement occurs when a third party makes, uses, sells, or imports an infringing product or process without authorization.
-
Litigation Environment: Malaysian courts have upheld patent rights in life sciences, but enforcement can be challenged through invalidity or non-infringement defenses.
-
No Post-Grant Oppositions: Malaysia does not currently offer post-grant opposition procedures. Challenges mainly arise through infringement actions or annulment suits.
-
Data Exclusivity: Malaysia does not provide data exclusivity in addition to patent rights, potentially opening pathways for generic entry after patent expiry.
Key Enforcement Factors
-
Clear claim scope aligned with patent disclosure.
-
Evidence of infringement, including product characterization and manufacturing process details.
-
Patentee must initiate legal action within statutory limits, generally six years from the date of infringement.
What Is the Scope of Claims for Biopharmaceutical Patents?
The scope of claims defines the extent of protection:
-
Product Claims: Cover specific molecules, drug formulations, or biological derivatives. They are highly enforceable if well drafted, with explicit structural or functional features.
-
Process Claims: Cover manufacturing methods, purification steps, or biological production techniques. These may face challenges if biological processes are deemed naturally occurring or non-patentable.
-
Use Claims: Cover specific therapeutic applications or methods of treatment. In Malaysia, methods of medical treatment are not patentable, but new uses of known compounds can be protected as "second medical use" patents if the claims are properly drafted.
-
Markush-Type Claims: Rarely used due to strict examination standards, but possible to define a class of compounds.
-
Claim Drafting Standards: Must clearly define the invention, avoiding overly broad or ambiguous language. Claims should be supported by the description and data.
Comparison to International Practices
Malaysia's scope restrictions are similar to other jurisdictions like Singapore or the UK but less lenient than the US or Europe. Biological process claims are limited, often requiring product or process claims to avoid exclusions.
Summary Table: Key Aspects for Biopharmaceutical Patents in Malaysia
| Aspect |
Details |
| Patentability |
Novelty, inventive step, utility; excludes biological processes and methods of treatment |
| Patent Subject Matter |
Products (molecules, formulations), processes (manufacturing) |
| Enforceability |
Requires proper patent validity; enforcement via civil litigation; no post-grant opposition |
| Scope of Claims |
Product, process, and use claims; must be precise and supported |
| Data Exclusivity |
Not granted; patent rights are primary protection |
Key Takeaways
-
Malaysian patent law allows protection of biopharmaceutical products but excludes biological processes and treatment methods.
-
Patent validity hinges on novelty and inventive step, with enforcement primarily through civil litigation.
-
Claims should focus on specific molecules or production processes. Use claims are restricted, as method claims on medical treatment are non-patentable.
-
Well-drafted patents with clear, supported claims increase enforceability chances.
FAQs
1. Can biological processes be patented in Malaysia?
Biological processes for producing biopharmaceuticals are generally excluded from patentability under Section 13 of the Patent Act. Only products and non-biological methods are patentable.
2. Are second medical use patents enforceable in Malaysia?
Yes. Second medical use or use claims can be protected if drafted as new uses of known compounds, provided they meet novelty and inventive step requirements.
3. How long does patent protection last?
20 years from the filing date, provided renewal fees are paid annually.
4. Can I patent genetically modified organisms in Malaysia?
Genetically modified organisms can be patented if they meet the criteria for patentability, excluding plant or animal varieties and certain biological methods.
5. Is patent opposition available post-grant in Malaysia?
No. Challenges to patent validity are typically made via infringement suits or invalidation proceedings, not through a post-grant opposition process.
References
- Patent Act 1983 (Malaysia).
- Malaysian Intellectual Property Corporation (MyIPO) guidelines.
- WIPO Patent Information Guide – Life Sciences.
